ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0852

Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration

Pamela Weiss1, Timothy Brandon2, Amita Aggarwal3, Ruben Burgos vargas4, Robert Colbert5, Gerd Horneff6, Rik Joos7, Ronald Laxer8, Kirsten Minden9, Angelo Ravelli10, Nicola Ruperto11, Judith Smith12, Matthew Stoll13, Shirley Tse8, Filip Van den bosch14, Walter P Maksymowych15, Robert G Lambert16, David Biko17, Nancy Chauvin18, Michael Francavilla17, Jacob Jaremko16, Nele Herregods19, Ozgur Kasapcopur20, Mehmet YILDIZ21 and Alison Hendry22, 1Children's Hospital of Philadelphia, Glen Mills, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 4hospital general de mexico, Ciudad de México, Mexico, 5NIH/NIAMS, Bethesda, MD, 6Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 7Ghent University Hospital, Basel, Switzerland, 8Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 9Charité Universitätsmedizin Berlin, Berlin, Germany, 10Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, 11IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, 12University of Wisconsin, Madison, WI, 13University of Alabama at Birmingham, Birmingham, AL, 14Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 15Department of Medicine, University of Alberta, Edmonton, AB, Canada, 16University of Alberta, Edmonton, AB, Canada, 17University of Pennsylvania, Philadelphia, PA, 18Penn State Health, Hershey, PA, 19Ghent University Hospital, Ghent, Belgium, 20Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, 21Istanbul University-Cerrahpaşa, Istanbul, Turkey, 22Middlemore Hospital, Auckland

Meeting: ACR Convergence 2022

Keywords: classification criteria, Pediatric rheumatology, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The lack of classification criteria for axial disease hinders the conduct of clinical trials for juvenile spondyloarthritis (JSpA). We aimed to develop candidate classification criteria to identify a homogeneous group of JSpA and axial disease for entry into clinical studies. These criteria are not intended to capture all possible subjects, but instead most patients with shared key features of axial disease.

Methods: Clinical factors relevant for distinguishing JSpA with axial disease from other similar conditions were identified during item generation/reduction exercises and then collected on a standardized case report form for 304 cases with JSpA and suspected axial disease from 6 international centers; all had an MRI with views of the pelvis reviewed by a team of musculoskeletal imaging experts. Clinical SpA experts (N=14) reviewed each patient and rated the likelihood the case represented JSpA with axial disease on a scale of -3 to +3. 20 cases representing the full spectrum of ratings were then scored and rank-ordered. The clinical expert panel reviewed the interrater agreement of case ranking, refined the criteria definitions and domain levels, and participated in a multi-criterion decision analysis exercise to generate relative weights of the criteria. Next, 30 cases from the derivation cohort were scored and ranked using the relative weights for each domain. Experts independently determined the score or “threshold” below which they were no longer confident that a patient should be classified as having axial disease. Results of this exercise were discussed and a provisional threshold score for classification was achieved by consensus.

Results: The preliminary axial disease criteria for juvenile SpA included the Paediatric Rheumatology International Trials Organization (PRINTO) provisional criteria for enthesitis/spondylitis-related juvenile idiopathic arthritis (JIA) or a rheumatologist diagnosis of JSpA as entry criteria as well as additive weighted criteria for 7 domains: sacroiliac joint (SIJ) active inflammation on imaging, SIJ structural lesions on imaging, pain chronicity, pain pattern, pain location, morning stiffness, and genetics. Interrater agreement of the pre-consensus meeting case rankings was poor with a Kendall’s correlation coefficient of 0.23. The multi-criterion decision analysis was repeated for the imaging domains when initial criteria weighting was not in accordance with the expert panel’s opinion. The multi-criterion decision analysis involved a total of 58 pairwise decisions agreed upon by expert consensus. After criteria weights and additive scores were re-calculated, experts reached consensus for axial disease in juvenile SpA for all cases scoring ≥55.

Conclusion: Using an iterative process, the JSpA axial disease criteria definitions were refined, preliminary weights were generated, and a provisional threshold score for classification was determined. The most heavily weighted domains were active inflammation and structural lesions on imaging. Imaging typical of sacroiliitis was necessary, but not sufficient without any clinical criterion, to surpass the axial disease classification threshold.

Supporting image 1

Levels within each domain are mutually exclusive. Highest level achieved within each domain contributes to the overall score. Scores ≥55 were deemed consistent with classification of axial disease. *Unequivocal evidence of active lesions typical of sacroiliitis on MRI of the sacroiliac joints: Subchondral bone marrow edema detectable in ≥3 sacroiliac joint quadrants on pelvic MRI which includes fluid sensitive sequences and semicoronal coronal slices through the cartilaginous portion of the joint. ^Unequivocal evidence of structural lesions typical of sacroiliitis on MRI of the sacroiliac joint: Any of the following lesions present on pelvic MRI (which includes T1-weighted sequences and semicoronal coronal slices through the cartilaginous portion of the joint): erosion in ≥3 quadrants or any of the following in ≥2 quadrants: sclerosis, fat lesion, backfill, ankylosis.


Disclosures: P. Weiss, None; T. Brandon, None; A. Aggarwal, None; R. Burgos vargas, None; R. Colbert, Eli Lilly; G. Horneff, Roche, Pfizer, Novartis, Merck/MSD, Eli Lilly, AbbVie/Abbott; R. Joos, None; R. Laxer, Eli Lilly, Novartis, sanofi, sobi; K. Minden, Novartis, Pfizer, Bristol-Myers Squibb(BMS), Roche, Biogen; A. Ravelli, None; N. Ruperto, 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic,, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB; J. Smith, None; M. Stoll, Novartis; S. Tse, None; F. Van den bosch, AbbVie, Lilly, Galapagos, Janssen, Merck, Novartis, Pfizer, UCB, Amgen, Bristol-Myers Squibb(BMS), Celgene; W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; R. Lambert, Calyx, CARE Arthritis, Image Analysis Group; D. Biko, None; N. Chauvin, None; M. Francavilla, None; J. Jaremko, None; N. Herregods, None; O. Kasapcopur, None; M. YILDIZ, None; A. Hendry, None.

To cite this abstract in AMA style:

Weiss P, Brandon T, Aggarwal A, Burgos vargas R, Colbert R, Horneff G, Joos R, Laxer R, Minden K, Ravelli A, Ruperto N, Smith J, Stoll M, Tse S, Van den bosch F, Maksymowych W, Lambert R, Biko D, Chauvin N, Francavilla M, Jaremko J, Herregods N, Kasapcopur O, YILDIZ M, Hendry A. Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-refinement-and-weighting-of-candidate-criteria-for-axial-disease-in-juvenile-spondyloarthritis-an-international-collaboration/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-refinement-and-weighting-of-candidate-criteria-for-axial-disease-in-juvenile-spondyloarthritis-an-international-collaboration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology